MedTrace Logo

Study to Evaluate the Pharmacokinetics of ANG-3777 in Hemodialysis Subjects

NCT04958187 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2021-07-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of a single-dose of ANG-3777 in subjects with renal failure receiving maintenance hemodialysis.

Conditions

  • Hemodialysis

Interventions

DRUG

ANG-3777

Arm assigned to this intervention will receive 2 mg/kg, IV

Sponsors & Collaborators

  • Nucleus Network Ltd

    collaborator OTHER

  • Angion Biomedica Corp

    lead INDUSTRY

Principal Investigators

  • Daniel K. Ries, MD · Nucleus Network Ltd

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-31
Primary Completion
2021-10-31
Completion
2021-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04958187 on ClinicalTrials.gov